Sun Pharma Advanced Research Company Ltd
Sun Pharma Advanced Research Company Q1 FY21 earnings call: Revenue & Margins
Q1 FY21 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #86 of 86 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Sun Pharma Advanced Research Company Ltd's Q1 FY21 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY21 Total Income: INR 1,861 Mn (~$24.5 Mn), up from Q1 FY20 Total Income: INR 210 Mn (~$3.0 Mn), indicating a significant year-on-year increase primarily due to a non-recurring upfront payment.
From Sun Pharma Advanced Research Company Ltd's Q1 FY21 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q1 FY21 Total Income: INR 1,861 Mn (~$24.5 Mn), up from Q1 FY20 Total Income: INR 210 Mn (~$3.0 Mn), indicating a significant year-on-year increase primarily due to a non-recurring upfront payment.
- Total Expenses in Q1 FY21: INR 1,294 Mn (~$17.1 Mn) vs Q1 FY20: INR 1,152 Mn (~$16.6 Mn).
- Profit after Tax in Q1 FY21: INR 567 Mn (~$7.5 Mn) vs loss of INR 942 Mn (~$-13.5 Mn) in Q1 FY20, reflecting turnaround due to a $20 Mn upfront licensing payment from SCD-044.
2 more points from Sun Pharma Advanced Research Company Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sun Pharma Advanced Research Company Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Sun Pharma Advanced Research Company Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sun Pharma Advanced Research Company Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- No references to pending orders or order fulfillment status.
- It provides details on clinical programs, financial performance figures, and strategic outlook but excludes operational order metrics.
Sun Pharma Advanced Research Company Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹30 Cr, net loss ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What SPARC's management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sun Pharma Advanced Research Company Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sun Pharma Advanced Research Company Ltd Q1 FY21 results?
Q1 FY21 Total Income: INR 1,861 Mn (~$24.5 Mn), up from Q1 FY20 Total Income: INR 210 Mn (~$3.0 Mn), indicating a significant year-on-year increase primarily due to a non-recurring upfront payment.
What is Sun Pharma Advanced Research Company Ltd share price analysis?
Sun Pharma Advanced Research Company Ltd currently shows a neutral. The stock trades at a P/E of 3.9 with a market cap of ₹6,293 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Sun Pharma Advanced Research Company Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.